申请人:Stoit Axel
公开号:US20090018160A1
公开(公告)日:2009-01-15
The present invention relates to heterocyclic compounds of the formula (I)
or a pharmaceutically acceptable salt, a solvate or hydrate thereof wherein
the heterocycle comprises two double bonds which may be present at several positions, and which are represented by the dashed lines (---);
the heterocycle contains two heteroatoms,
W is N or NH;
Y is CH, O or NH, wherein
if Y is O, X
1
is CH and X
2
is C-Z-R2 or C—R3, wherein Z is NH, O, or S; and
if Y is CH or NH, one of X
1
and X
2
is CH or N, wherein if X
1
is CH or N, X
2
is C-Z-R2 or C—R3, and if X
2
is CH or N, X
1
is C-Z-R2 or C—R3, wherein Z is NH or S;
R1 is chosen from structures (a), (b) and (c):
R2 is chosen from (C
1
-C
10
)alkyl, (C
2
-C
10
)alkenyl and (C
2
-C
10
)alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, oxo, (C
1
-C
6
)alkoxy, (C
1
-C
6
)alkylthio, (C
1
-C
6
)alkenyloxy, (C
1
-C
6
)alkenylthio, (C
1
-C
4
)alkoxy(C
1
-C
4
)alkoxy, (C
5
-C
7
)cycloalkyl, a 5-membered unsaturated heterocycle (optionally substituted with halogen), phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and
R3 is chosen from (C
4
-C
10
)alkyl, (C
2
-C
10
)alkenyl and (C
2
-C
10
)alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, (C
1
-C
6
)alkoxy, (C
1
-C
6
)alkylthio, (C
1
-C
6
)alkenyloxy, (C
1
-C
6
)alkenylthio, (C
1
-C
4
)alkoxy(C
1
-C
4
)alkoxy, (C
5
-C
7
)cycloalkyl, a 5-membered unsaturated heterocycle optionally substituted with halogen, phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen;
and optionally, when R2 is an unbranched (C
2
-C
8
)alkyl, R2 links to formula (Ia)
or a pharmaceutically acceptable salt, a solvate or hydrate thereof,
through the X
1
a or X
2
a of formula (Ia), wherein if X
1
is CH or N, X
1
a is CH or N and X
2
a is C-Za-, or
if X
1
is C-Z-R2, X
1
a is C-Za- and X
2
a is CH or N, wherein X
1
a or X
2
a having Za links to R2; and
the symbols Wa, Ya and Za and the substituent R1
a
have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1
a
representing identical symbols and substituents, respectively, as the symbols W, Y and Z and the substituent R1 in the other part of the structure of formula (I). The compounds of the invention have affinity to muscarinic receptors and may be used in the treatment, alleviation or prevention of muscarinic receptor mediated diseases and conditions.
本发明涉及公式(I)的杂环化合物或其药学上可接受的盐、溶剂或水合物,其中杂环包含两个双键,可以存在于多个位置,并由虚线(---)表示;杂环含有两个杂原子,W为N或NH;Y为CH,O或NH,其中如果Y为O,X1为CH,X2为C-Z-R2或C—R3,其中Z为NH,O或S;如果Y为CH或NH,X1和X2中的一个为CH或N,其中如果X1为CH或N,X2为C-Z-R2或C—R3,如果X2为CH或N,则X1为C-Z-R2或C—R3,其中Z为NH或S;R1选择自结构(a)、(b)和(c):R2选择自(C1-C10)烷基,(C2-C10)烯基和(C2-C10)炔基,可选地独立取代一个或多个取代基,所选的取代基选择自卤素,羟基,氰基,氧代基,(C1-C6)烷氧基,(C1-C6)烷基硫基,(C1-C6)烯基氧基,(C1-C6)烯基硫基,(C1-C4)烷氧基(C1-C4)烷氧基,(C5-C7)环烷基,一种5-成员不饱和杂环(可选地取代卤素),苯基,苯氧基和苯硫基,其中苯基可选地取代卤素;R3选择自(C4-C10)烷基,(C2-C10)烯基和(C2-C10)炔基,可选地独立取代一个或多个取代基,所选的取代基选择自卤素,羟基,氰基,(C1-C6)烷氧基,(C1-C6)烷基硫基,(C1-C6)烯基氧基,(C1-C6)烯基硫基,(C1-C4)烷氧基(C1-C4)烷氧基,(C5-C7)环烷基,一种5-成员不饱和杂环,可选地取代卤素,苯基,苯氧基和苯硫基,其中苯基可选地取代卤素;可选地,当R2为直链(C2-C8)烷基时,R2通过公式(Ia)或其药学上可接受的盐、溶剂或水合物与公式(I)连接,其中如果X1为CH或N,X1a为CH或N,X2a为C-Za-,或如果X1为C-Z-R2,X1a为C-Za-,X2a为CH或N,其中X1a或X2a具有Za连接到R2;符号Wa,Ya和Za和取代基R1a具有与先前定义的符号W,Y和Z和取代基R1相同的含义,并且不能独立选择,每个符号Wa,Ya和Za和取代基R1分别表示与公式(I)结构的其他部分中的符号W,Y和Z和取代基R1相同的符号和取代基。本发明的化合物具有亲和力,可以用于治疗、缓解或预防毒蕈碱受体介导的疾病和症状。